NASDAQ : QNRX
Quoin Pharmaceuticals, Ltd. — Financial statements
Healthcare · Biotechnology · United States
Last price 4.54 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 21.81M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 6.71M | 6.49M | 5.93M | 6.07M | 6.58M | 4.50M |
| Research & Development | 12.44M | 9.80M | 3.60M | 3.31M | 2.67M | 1.56M |
| Operating Expenses | 19.15M | 16.29M | 9.53M | 9.38M | 9.26M | 6.06M |
| Operating Income | -19.15M | -16.29M | -9.53M | -9.38M | -9.26M | -6.06M |
| Interest Expense | -714.08K | -1.37M | ||||
| Interest & Investment Income | 481.69K | 482.08K | 558.49K | 694.61K | 95.75K | |
| Other Non Operating Income (Expenses) | -1.86K | 3.98K | 7.50K | -2.68K | 78.54K | -12.78M |
| EBT Excluding Unusual Items | -18.67M | -15.80M | -8.96M | -8.69M | -9.80M | -20.21M |
| Other Unusual Items | 416.00K | -1.25M | ||||
| Pretax Income | -18.67M | -15.80M | -8.96M | -8.69M | -9.38M | -21.46M |
| Net Income | -18.67M | -15.80M | -8.96M | -8.69M | -9.38M | -21.46M |
| Preferred Dividends & Other Adjustments | 65.27K | |||||
| Net Income to Common | -18.67M | -15.80M | -8.96M | -8.69M | -9.45M | -21.46M |
| Shares Outstanding (Basic) | 2.19M | 1.07M | 131.76K | 25.74K | ||
| Shares Outstanding (Diluted) | 2.19M | 1.07M | 131.76K | 25.74K | ||
| EPS (Basic) | -8.52 | -14.80 | -68.02 | -337.46 | ||
| EPS (Diluted) | -8.52 | -14.80 | -68.02 | -337.46 | ||
| EBITDA | -19.05M | -16.19M | -9.43M | -9.27M | -9.15M | -5.96M |
| D&A For EBITDA | 100.00K | 100.00K | 100.00K | 103.71K | 104.04K | 104.04K |
| EBIT | -19.15M | -16.29M | -9.53M | -9.38M | -9.26M | -6.06M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 3.85M | 3.82M | 3.62M | 2.40M | 2.86M | 7.48M |
| Short-Term Investments | 6.95M | 14.93M | 10.43M | 8.29M | 9.99M | |
| Cash & Short-Term Investments | 10.80M | 18.75M | 14.06M | 10.69M | 12.85M | 7.48M |
| Prepaid Expenses | 160.17K | 1.26M | 869.13K | 591.03K | 516.58K | 715.47K |
| Other Current Assets | 675.98K | |||||
| Total Current Assets | 11.64M | 20.01M | 14.93M | 11.29M | 13.37M | 8.20M |
| Other Intangible Assets | 333.33K | 383.33K | 483.33K | 583.33K | 704.56K | 808.60K |
| Other Long-Term Assets | 300.00K | 300.00K | 383.39K | 350.00K | ||
| Total Assets | 11.97M | 20.39M | 15.71M | 12.17M | 14.46M | 9.36M |
| Accounts Payable | 3.11M | 1.26M | 905.70K | 526.52K | 605.60K | 923.24K |
| Accrued Expenses | 2.90M | 3.68M | 2.68M | 2.45M | 2.32M | 2.43M |
| Current Portion of Long-Term Debt | 600.00K | 600.00K | 600.00K | 600.00K | 600.00K | 600.00K |
| Other Current Liabilities | 623.60K | |||||
| Total Current Liabilities | 6.61M | 5.55M | 4.18M | 3.58M | 3.53M | 4.58M |
| Long-Term Debt | 1.42M | 1.72M | 2.32M | 2.92M | 3.52M | 4.12M |
| Total Liabilities | 8.04M | 7.27M | 6.50M | 6.51M | 7.05M | 8.70M |
| Additional Paid-In Capital | 85.27M | 84.09M | 64.37M | 51.87M | 47.86M | 31.66M |
| Retained Earnings | -81.34M | -70.97M | -55.17M | -46.20M | -37.52M | -28.07M |
| Treasury Stock | -2.93M | -2.93M | ||||
| Comprehensive Income & Other | -582.00 | -613.00 | ||||
| Shareholders' Equity | 3.93M | 13.12M | 9.20M | 5.66M | 7.41M | 657.03K |
| Total Liabilities & Equity | 11.97M | 20.39M | 15.71M | 12.17M | 14.46M | 9.36M |
| Total Debt | 2.02M | 2.32M | 2.92M | 3.52M | 4.12M | 4.72M |
| Net Cash (Debt) | 8.78M | 16.42M | 11.13M | 7.17M | 8.73M | 2.76M |
| Net Cash Per Share | 4.01 | 15.37 | 84.50 | 278.59 | ||
| Filing Date Shares Outstanding | 2.01M | 1.80M | 588.17K | 105.31K | 28.21K | |
| Total Common Shares Outstanding | 2.01M | 1.50M | 255.66K | 28.21K | 11.54K | |
| Working Capital | 5.02M | 14.46M | 10.75M | 7.70M | 9.84M | 3.62M |
| Book Value Per Share | 1.96 | 8.76 | 36.00 | 200.81 | 641.72 | |
| Tangible Book Value | 3.60M | 12.74M | 8.72M | 5.08M | 6.70M | -151.57K |
| Tangible Book Value Per Share | 1.79 | 8.50 | 34.11 | 180.13 | 580.68 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -18.67M | -15.80M | -8.96M | -8.69M | -9.38M | -21.46M |
| Depreciation & Amortization | 100.00K | 100.00K | 100.00K | 103.71K | 104.04K | 104.04K |
| Other Amortization | 275.00K | |||||
| Asset Writedown & Restructuring Costs | 17.52K | |||||
| Loss (Gain) From Sale of Investments | -238.88K | -215.85K | -251.59K | -489.08K | -93.78K | |
| Stock-Based Compensation | 1.44M | 1.15M | 1.26M | 1.09M | 764.01K | |
| Other Operating Activities | 220.84K | 14.73M | ||||
| Change in Accounts Payable | 2.23M | 1.33M | 275.95K | 53.92K | -217.81K | 1.35M |
| Change in Other Net Operating Assets | -147.21K | -92.85K | -278.09K | 41.52K | 123.45K | -715.47K |
| Operating Cash Flow | -15.27M | -13.54M | -7.86M | -7.86M | -8.48M | -5.72M |
| Investment in Securities | -593.77K | -4.28M | -1.89M | 2.19M | -9.90M | |
| Other Investing Activities | -250.00K | -625.00K | ||||
| Investing Cash Flow | -593.77K | -4.28M | -1.89M | 2.19M | -10.15M | -625.00K |
| Short-Term Debt Issued | 3.48M | |||||
| Long-Term Debt Issued | 139.28K | |||||
| Total Debt Issued | 3.61M | |||||
| Short-Term Debt Repaid | -311.67K | |||||
| Long-Term Debt Repaid | -600.00K | -600.00K | -600.00K | -600.00K | -304.47K | |
| Total Debt Repaid | -600.00K | -600.00K | -600.00K | -600.00K | -911.67K | -304.47K |
| Net Debt Issued (Repaid) | -600.00K | -600.00K | -600.00K | -600.00K | -911.67K | 3.31M |
| Issuance of Common Stock | 18.65M | 18.61M | 11.57M | 5.85M | 14.88M | 10.10M |
| Other Financing Activities | -32.58K | 42.05K | 91.34K | |||
| Financing Cash Flow | 18.05M | 18.01M | 10.97M | 5.22M | 14.01M | 13.50M |
| Foreign Exchange Rate Adjustments | -582.00 | -613.00 | ||||
| Net Cash Flow | 2.18M | 194.75K | 1.22M | -459.43K | -4.62M | 7.16M |
| Levered Free Cash Flow | -8.00M | -7.96M | -4.28M | -4.68M | -6.21M | -7.63M |
| Unlevered Free Cash Flow | -8.00M | -7.96M | -4.28M | -4.68M | -5.77M | -7.06M |
| Cash Interest Paid | 393.61K | |||||
| Change in Working Capital | 2.09M | 1.23M | -2.14K | 95.45K | -94.35K | 632.33K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 21.81M | 12.11M | 5.33M | 4.84M | 6.88M | 15.19M |
| Enterprise Value | 13.03M | 9.17M | -1.91M | -5.47M | -4.00M | 20.75M |
| Last Close Price | 4.54 | 14.43 | 22.77 | 171.68 | 596.40 | 9,555.01 |
| PB Ratio | 2.32 | 0.92 | 0.58 | 0.85 | 0.93 | 23.12 |
| P/TBV Ratio | 6.06 | 0.95 | 0.61 | 0.95 | 1.03 | |
| Debt / Equity Ratio | 0.52 | 0.18 | 0.32 | 0.62 | 0.56 | 7.19 |
| Net Debt / Equity Ratio | -2.23 | -1.25 | -1.21 | -1.27 | -1.18 | -4.20 |
| Net Debt / EBITDA Ratio | 0.46 | 1.01 | 1.18 | 0.77 | 0.95 | 0.46 |
| Quick Ratio | 1.63 | 3.38 | 3.36 | 2.99 | 3.64 | 1.64 |
| Current Ratio | 1.76 | 3.61 | 3.57 | 3.15 | 3.79 | 1.79 |
| Return on Equity (ROE) | -575.73% | -141.59% | -120.55% | -132.92% | -232.68% | |
| Return on Assets (ROA) | -114.60% | -56.41% | -42.72% | -44.03% | -48.59% | -70.60% |
| Return on Capital Employed (ROCE) | -357.40% | -109.70% | -82.70% | -109.20% | -84.70% | -126.80% |
| Earnings Yield | -187.69% | -130.55% | -168.23% | -179.39% | -136.30% | -141.27% |
| Buyback Yield / Dilution | -485.24% | -710.69% | -411.86% |